Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par Gets Pumped: Teva To Divest $200 Million Of Products To Acquire Cephalon

This article was originally published in The Pink Sheet Daily

Executive Summary

FTC requires Teva to sell its generic versions of Actiq and Amrix to Par; Teva will also supply Par with generic Provigil for one year.
Advertisement

Related Content

Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products
Deals Of The Week: Express Scripts/Walgreens, Par/TPG, Amicus/GSK
Par Acquisition By TPG Allows Competing Marriage Proposals
Teva Gets FTC Okay For Cephalon Deal After Reducing Its Generic Provigil Exclusivity
Provigil Generic Exclusivity Decision “Eviscerates” Hatch-Waxman, FTC Says
With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations
With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations
Grifols To Divest Factor VIII Product Koate To Merge With Talecris
Novartis/Alcon Merger Clears FTC Hurdle With Minor Divestiture, But Shareholder Battle Continues
FTC Approves the Pfizer-Wyeth Deal And Keeps Their Human Drug Portfolio Intact

Topics

Advertisement
UsernamePublicRestriction

Register

PS072876

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel